Keywords
Ocular Hypertension
Treatments
Ophthalmology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the literature on treatments for glaucoma associated with ocular hypertension. Literature review: Standard treatment for glaucoma and ocular hypertension is mainly performed via topical monotherapy (use of eye drops), especially with prostaglandin analogues (such as latanoprost, latanoprosten and tafluprost). Within this context, such eye drops in their versions without preservatives have, in general, greater tolerability, safety, and the same desired effect as their versions with preservatives. In addition to prostaglandin analogues, the treatment of glaucoma and ocular hypertension can also be performed with topical beta-adrenoblocker monotherapies (timolol and betaxolol), although their inferiority to prostaglandins has been demonstrated. Another important finding was that the long-term results of trabeculoplasty, if compared with the use of eye drops, would be better and more cost-effective than standard treatment. Final considerations: Based on the findings of this review, it is suggested that clinical trials be carried out involving the aforementioned treatments, seeking robust scientific evidence of their effectiveness in the treatment of ocular hypertension.
References
CHABI A, et al. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. Int J Clin Pract., 2016; 70(7): 577–86.
CHAMARD C, et al. Prevalence of Unknown Ocular Hypertension, Glaucoma Suspects, and Glaucoma in Patients Seen in an Ophthalmology Center in France. Ophthalmic Res., 2020; 63(3): 295–301.
CHI W, et al. Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. Eye Sci., 2013; 28(4): 190–4.
CONLON R, et al. Glaucoma treatment trends: a review. Can J Ophthalmol J Can Ophtalmol., 2017; 52(1): 114–24.
DENIS P e MONOPROST FRENCH STUDY GROUP. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study]. J Fr Ophtalmol., 2016; 39(7): 622–30.
DURU Z e OZSAYGILI C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. Cutan Ocul Toxicol., 2020; 39(1): 21–4.
EVELETH D, et al. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. BMC Ophthalmol., 2012; 12: 9.
FOGAGNOLO P e ROSSETTI L. Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs, 2011; 20(7): 947–59.
GARCIA-MEDINA JJ, et al. Glaucoma and Antioxidants: Review and Update. Antioxid Basel Switz, 2020; 9(11): E1031.
GAZZARD G, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet Lond Engl., 2019; 393(10180): 1505–16.
GOEL M, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010; 4: 52–9.
GOLAN S, et al. Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clin Exp Pharmacol Physiol., 2015; 42(2): 220–4.
GUGLIELMI P, et al. Novel therapies for glaucoma: a patent review (2013-2019). Expert Opin Ther Pat., 2019; 29(10): 769–80.
HUANG AS, et al. Structural and functional imaging of aqueous humour outflow: a review. Clin Experiment Ophthalmol., 2018; 46(2): 158–68.
JAYARAM H. Intraocular pressure reduction in glaucoma: Does every mmHg count? Taiwan J Ophthalmol., 2020; 10(4): 255–8.
KARLOVA EV, et al. [Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204)]. Vestn Oftalmol., 2020; 136(4): 76–84.
KASS MA, et al. Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up. JAMA Ophthalmol., 2021; 139(5): 558–66.
LUSTHAUS J e GOLDBERG I. Current management of glaucoma. Med J Aust., 2019; 210(4): 180–7.
MANASSES DT, et al. The New Era of Glaucoma Micro-stent Surgery. Ophthalmol Ther., 2016; 5(2): 135–46.
MARSHALL LL, et al. Therapy for Open-Angle Glaucoma. Consult Pharm J Am Soc Consult Pharm., 2018; 33(8): 432–45.
MISIUK-HOJLO M, et al. The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol., 2019; 29(2): 210–5.
RAZEGHINEJAD MR e LEE D. Managing normal tension glaucoma by lowering the intraocular pressure. Surv Ophthalmol. fevereiro de 2019;64(1):111–6.
SCHEHLEIN EM, et al. New classes of glaucoma medications. Curr Opin Ophthalmol., 2017; 28(2): 161–8.
SKRZYPECKI J, et al. A common humoral background of intraocular and arterial blood pressure dysregulation. Curr Med Res Opin., 2018; 34(3): 521–9.
TANITO M e MATSUO M. Ab-interno trabeculotomy-related glaucoma surgeries. Taiwan J Ophthalmol., 2019; 9(2): 67–71.
WANG T, et al. Topical Medication Therapy for Glaucoma and Ocular Hypertension. Front Pharmacol., 2021; 12: 749858.
WEBB TER. A review of glaucoma surgical therapy. Vet Ophthalmol., 2021; 24 Suppl 1: 34–8.
WEINREB RN, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol., 2015; 99(6): 738–45.